CRT's stock is down on heavy volume as a blog post from the husband of treated Patient #2 reported that she has stopped therapy due to a mutation (https://www.givesendgo.com/Woldt). While social media post are not company press releases and in the vast majority of situations must be taken with a grain of salt, there appears to be some validity here. With data from the objective response (OR) seen in Patient #1 - who has lung cancer - about to be presented on September 30, we are buyers of TCRT here on weakness. BUY. Details from GoFundMe Blog Now all of this from the unsolicited blog/link above. The woman has advanced colon cancer which was targeted with P53 mutation from the TCR-T Library. She started treatment late-Spring/early Summer that initially resulted in a 27% tumor reduction. The mutation appears to have occurred after recent blood work was performed at MD Andersen. A mutation in colon cancer is not unheard of as colon cancer is known to often mutate when under pressure, i.e. chemotherapy. Importantly and despite the setback in treatment, the patient is healthy enough to resume chemotherapy and did not appear to suffer any platform-related side effects that might have a negative read through to TCRT. Hence is the beauty of the Alaunos' Sleeping Beauty kill switch and stopping the overactive immune response before it gets out of control. As a reminder, all of this is unconfirmed although the blog and its details appear legit.
Patient #1 Is Key
Most importantly, Alaunos recently confirmed that it has seen an objective partial response (OR) in the first patient treated in the study. Patient #1 has non-small c lung cancer, and had one prior line of adjuvant therapy following surgery and thre prior lines of systemic therapy. The patient has a tumor with a KRAS G12D mutation, not P53. The patient was treated at the first dose level with TCR-T cells. an objective response was observed and has now cleared the 28-day safety window. TCRT will report initial data from the study on Friday, September 30, 8:30am ET at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference.
A LOT MORE TO COME
In our view, the TCR-T platform has the ability to treat solid tumors with CAR-T therapy, and the setback with Patient #2 will be a learning event for the Company. The proprietary safety kill switch is a life saver in immuno-oncology. With only two very late-stage patients having been treated, a 50% overall response rate (ORR) would be more than acceptable. The Company is advancing it's TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications, obviously the first being lung, the second colorectal. We expect the upcoming detailed data from Patient #1 will be positive and help the stock to regain its momentum. As we know that different tumors respond differently and this is a very small sample size we are dealing with; hence, the wild volatility in TCRT shares. However, we know for sure that the platform has resulted in at least one objective response in a very advanced lung cancer patient at the first dose, and that patient has been cleared by the FDA to advance to the next dose. We are buyers on this weakness.
Market Data 
Markets 
AI
